'Rituximab maintenance' presentation slideshows

RTP TV: An 8-Part Live CME Webcast Series

914 views • 78 slides

Therapy for Follicular Lymphoma

714 views • 45 slides

Current and Emerging Advances in Mantle Cell Lymphoma

Current and Emerging Advances in Mantle Cell Lymphoma. Mantle Cell Lymphoma Atypical Cases. Mantle Cell Lymphoma Current Treatment Paradigm. Rituximab Maintenance vs ASCT E1405 Study. Mantle Cell Lymphoma Older Patient With Comorbidities.

1.01k views • 41 slides

Chairman of the Dutch Hematology Society Chairman of the HOVON CLL Group

Marinus van Oers Professor of Hematology/Head of the Department of Clinical Hematology, Academic Medical Center, University of Amsterdam, The Netherlands. Chairman of the Dutch Hematology Society Chairman of the HOVON CLL Group

569 views • 38 slides

G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo, R. Bouabdallah,

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy. G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo, R. Bouabdallah,

502 views • 28 slides

356 views • 27 slides

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy ? Radio

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy ? Radioimmunotherapy ! . Matthew Matasar, MD MS Assistant Member, Lymphoma and Adult BMT Services Memorial Sloan-Kettering Cancer Center New York, NY.

383 views • 23 slides

Extending survival in relapsed indolent lymphoma with induction and maintenance

366 views • 21 slides

459 views • 18 slides

Salles GA et al. Proc ASCO 2010;Abstract 8004.

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy. Salles GA et al. Proc ASCO 2010;Abstract 8004. Introduction.

258 views • 11 slides

Bosch F et al. Proc ASH 2011;Abstract 293.

Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). Bosch F et al.

180 views • 8 slides

106 views • 3 slides